ClinicalTrials.gg
Active, not recruitingNCT07029555Updated Jun 30, 2026

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

A Phase 1 interventional study of PIT565 in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 16 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Arthritis, Rheumatoid by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.

Planned enrollment
22nd of 30
57 · median 98
Started
2025
with 1 other
Phase 1
7 of 30
1 open now
Registered
28th of 30
by date

Among the 30 studies in Arthritis, Rheumatoid by Novartis, this one is the 22nd largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 28th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 30 studies in Arthritis, Rheumatoid by Novartis is open now. Recruiting first, the newest first:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Arthritis, Rheumatoid by Novartis, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).

Read the detailed description

This is an open-label, uncontrolled study in participants with RA. PIT565 will be administered subcutaneously. The objective of the study is to assess the safety of PIT565 in participants with RA.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • PIT565
  • ascending dose
  • rheumatoid arthritis
  • B cells
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study. Male and female patients, aged 18 to 75 years at screening, diagnosed with RA according to the 2010 ACR/EULAR or 1987 ACR classification at least 12 weeks prior to screening.
  • Immunization (primary or from vaccinations) against pneumococcus, influenza, meningococcus and COVID-19 infection at least 2 weeks prior to the first dosing. Local guidelines should be followed to determine requirement for vaccination (or booster), as well as the type and schedule of vaccination.

Exclusion criteria

Exclusion Criteria:

  • Any of the following cardiac conditions
  1. Unstable angina, myocardial infarction, coronary artery bypass graft (CABG), or stroke within 6 months prior to screening
  2. and/or uncontrolled heart disease such as congestive heart failure requiring treatment ( Grade ≥ 2) or uncontrolled hypertension
  3. Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree atrioventricular block without a pacemaker
  4. History of familial long syndrome or known family history of Torsades-de- Pointes
  5. Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) at screening
  6. Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    PIT565 dose 1

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 2

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 3

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 4

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 5

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 6

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 7

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

  • Experimental
    PIT565 dose 8

    Study treatment will be provided in vials as open-label participant specific supply.

    Biological: PIT565

Interventions

  • BiologicalPIT565

    Study treatment will be provided in vials as open-label participant specific supply.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

    Time frame: 6 months

Secondary outcomes

  1. Pharmacokinetic parameters of PIT565: Maximum serum Concentration [Cmax]

    Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)

    Time frame: up to 6 months

  2. Pharmacokinetic parameters of PIT565: Area under serum concentration (AUC)

    AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1).

    Time frame: up to 6 months

  3. Concentrations of anti-PIT565 antibodies

    To assess the immunogenicity (IG) of PIT565

    Time frame: Baseline, up to 6 months

07

Study locations

16 sites
  • Novartis Investigative Site
    Pilar, Buenos Aires B1629AHJ, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Sofia, 1618, Bulgaria
  • Novartis Investigative Site
    Beijing, 100191, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Leiden, South Holland 2333 CL, Netherlands
  • Novartis Investigative Site
    Cluj-Napoca, Cluj 400006, Romania
  • Novartis Investigative Site
    Bucharest, 011658, Romania
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 35 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartActual
Jun 12, 2025
Primary completionEst.
May 15, 2028
CompletionEst.
May 16, 2028
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07029555
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Jun 12, 2025
Primary completion
May 15, 2028 (estimated)
Completion
May 16, 2028 (estimated)
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565

Start the discussion